October 20, 2026
Quantum BioPharma’s Unbuzzd Draws Scrutiny and Interest After Men’s Fitness Report on Clinical Trial
October 20, 2026
NanoViricides Reports Positive Juvenile Safety Data for NV-387, But Going Concern Risk Persists
October 19, 2026
Quantum BioPharma’s Unbuzzd Shows Promise in Alcohol Recovery Trial, But Questions Remain
October 15, 2026
Tonix Pharmaceuticals to Present TNX-801 Vaccine Platform at World Vaccine Congress Europe
October 15, 2026
OrthodontiCell Secures Capital to Complete Testing for Planned U.S. Phase II Pivotal Study
October 15, 2026
hyperCORE International Elects New Officers to Drive Growth for Site Networks and CROs
October 14, 2026
Quantum BioPharma Wins FDA Clearance to Test Lucid-MS, a Non-Immune Approach to Multiple Sclerosis
October 13, 2026
Leksum Inks Agreement with Medical University of Vienna for Preparatory Work Leading to Phase I/II Clinical Trials of LK-ICU
October 12, 2026
American Heart Association Expands Education to Help Clinicians Apply New Cardiovascular-Kidney-Metabolic Syndrome Guideline
October 7, 2026
Quantum BioPharma Taps Thermo Fisher to Run Phase 2 Trial of Neuroprotective MS Drug Lucid-MS
October 7, 2026
Quantum BioPharma Taps Thermo Fisher for Phase 2 Lucid-MS Trial, Advancing Novel Neuroprotective Approach
October 7, 2026
Quantum BioPharma Taps Thermo Fisher to Launch Phase 2 Trial of Lucid-MS for Progressive MS
October 6, 2026
Quantum BioPharma Taps Thermo Fisher for Lucid-MS Phase 2 Trial in Multiple Sclerosis
October 6, 2026
NanoViricides to Present at NIBA Conference as NV-387 Advances in Ebola and Mpox Trials
October 6, 2026
Okogen Secures CDSCO Authorization for EMERALD Phase 1/2 Study of Treyegen™ (OKG-0303) for Acute Infectious Conjunctivitis
October 5, 2026
NanoViricides Advances Phase II Trial of Oral Ebola Treatment as Congo Outbreak Continues
October 1, 2026
Incannex Healthcare’s Lead Cannabinoid Drug Enters Active Clinical Execution as Stonegate Updates Coverage
October 1, 2026
New Medical Thriller The Vena Protocol: First Blood Examines Clinical Trial Integrity
September 30, 2026
Quantum BioPharma Advances Lucid-MS to Phase 2 Trial, Highlights Royalty Stream from unbuzzd
September 30, 2026
Quantum BioPharma Co-Founder Details Lucid-MS Phase 2 Trial and unbuzzd Commercial Prospects on BioMedWire Podcast
September 29, 2026
Survey Finds Most US Adults Support Vaccines, But Uncertainty Leaves Millions Unvaccinated
September 29, 2026
NanoViricides Reports Fiscal 2026 Results, Advances NV-387 Phase II Trials for Mpox and Ebola
September 25, 2026
Quantum BioPharma’s Lucid-MS Clears FDA Hurdle for Phase 2 Multiple Sclerosis Trial
September 25, 2026
Creative Biolabs Introduces Three-Part Antibody Engineering Framework to Streamline Preclinical Development
September 24, 2026
FamiCord AG Signs Manufacturing Agreement with VERIGRAFT for Pivotal Phase II/III Trial of Personalized Tissue-Engineered Vein
September 23, 2026
American Heart Association to Honor Kidney Disease Researcher Dr. Katherine Tuttle with 2026 Clinical Research Prize
September 23, 2026
Boston BioLife to Co-Present Translational Longevity Summit at Harvard Enterprise Research Campus
September 21, 2026
In Vitro ADME Studies Streamline Drug Development, Creative Bioarray Offers Comprehensive Services
September 17, 2026
Peptide Wholesale Supply Expands HPLC Batch Traceability to Bulk Semaglutide and Tirzepatide Orders
September 11, 2026
Regentis Biomaterials Advances GelrinC Pivotal Trial and Reports First Half 2026 Results
September 11, 2026
Quantum BioPharma’s Lucid-MS Advances to Phase 2 Trial as First Myelin-Rebuilding Approach for MS
September 11, 2026
Regentis Biomaterials Advances GelrinC as Potential New Approach to Knee Cartilage Repair
September 11, 2026
Creative Biolabs Expands Functionalized Lipid Delivery to Overcome Key Research Barriers
September 10, 2026
VERAXA Biotech Appoints Dr. Christoph Erkel as CSO to Steer BiTAC® Toward Clinical Trials
September 10, 2026
Quantum BioPharma Advances Multiple Sclerosis Drug Lucid-MS Toward Phase 2 Trial After FDA Clearance
September 10, 2026
FDA Clearance of Quantum BioPharma’s Lucid-MS Marks First Myelin-Repair Approach in MS
September 10, 2026
FDA Clearance of Quantum BioPharma’s Lucid-MS Marks First Myelin-Repair Approach to Multiple Sclerosis
September 10, 2026
Onco-Innovations CMO Highlights Dual Mechanism of PNKP Inhibitor ONC010 in BioMedWire Podcast
